Relacorilant (glucocorticoid receptor antagonist) + nab-paclitaxel extends OS by 4.1 months in platinum-resistant ovarian cancer

Relacorilant is a first-in-class, selective glucocorticoid receptor (GR) antagonist intended to counter GR-mediated chemotherapy resistance, and was combined with weekly nab-paclitaxel in the Phase 3 ROSELLA trial (GOG-3073; NCT05257408) in platinum-resistant ovarian cancer (n=381) versus nab-paclitaxel alone (dose-reduced in the combo arm: 80 mg/m² vs 100 mg/m²). At final OS analysis (288 deaths; 76% maturity; median follow-up 24.8 months), the combination improved OS to 16.0 vs 11.9 months (HR 0.65, 95% CI 0.51–0.83; p=0.0004); as a benchmark, historical nab-paclitaxel monotherapy in platinum-resistant disease has shown ORR ~23% with median PFS ~4.5 months and OS ~17.4 months in a GOG Phase 2 dataset (cross-trial comparisons apply). Taxane pretreatment was essentially universal (99.5%), and the OS benefit was directionally consistent across “taxane-free interval” (≤6 months: HR 0.60; >6 months: HR 0.66) and whether a taxane was part of the most recent regimen (taxane last: HR 0.67; no taxane last: HR 0.63); safety was stated as similar to nab-paclitaxel alone, but Grade 3+ AE details were not provided in this abstract.